Articaine

Identification

Name
Articaine
Accession Number
DB09009
Type
Small Molecule
Groups
Approved
Description

Articaine is a dental local anesthetic. It is the most widely used local anesthetic in a number of European countries and is available in many countries around the world.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Articaine hydrochlorideQS9014Q79223964-57-0GDWDBGSWGNEMGJ-UHFFFAOYSA-N
International/Other Brands
Septocaine
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
4% Astracaine Dental With Epinephrine 1:200,000 (0.005mg/ml)Articaine hydrochloride (40 mg) + Epinephrine (0.005 mg)SolutionInfiltrationDentsply Pharmaceutical1997-02-262003-11-28Canada
4% Astracaine Dental With Epinephrine 1:200,000 (0.005mg/ml)Articaine hydrochloride (40 mg) + Epinephrine (0.005 mg)SolutionInfiltrationDentsply Pharmaceutical2004-01-29Not applicableCanada
4% Astracaine Dental With Epinephrine Forte 1:100,000 (0.01mg/ml)Articaine hydrochloride (40 mg) + Epinephrine (0.01 mg)SolutionInfiltrationDentsply Pharmaceutical1997-02-262003-11-28Canada
4% Astracaine Dental With Epinephrine Forte 1:100,000 (0.01mg/ml)Articaine hydrochloride (40 mg) + Epinephrine (0.01 mg)SolutionInfiltrationDentsply Pharmaceutical2004-01-29Not applicableCanada
ArticadentArticaine hydrochloride (40 mg/mL) + Epinephrine bitartrate (.01 mg/mL)Injection, solutionSubcutaneousDentsply Pharmaceutical2000-04-03Not applicableUs
ArticadentArticaine hydrochloride (40 mg/mL) + Epinephrine bitartrate (.005 mg/mL)Injection, solutionSubcutaneousDentsply Pharmaceutical2000-04-03Not applicableUs
ArticaineArticaine hydrochloride (40 mg/mL) + Epinephrine bitartrate (.01 mg/mL)Injection, solutionSubcutaneousBenco Dental2016-04-04Not applicableUs
ArticaineArticaine hydrochloride (40 mg/mL) + Epinephrine bitartrate (.01 mg/mL)Injection, solutionSubcutaneousDarby Dental Supply Llc2017-03-01Not applicableUs
ArticaineArticaine hydrochloride (40 mg/mL) + Epinephrine bitartrate (.005 mg/mL)Injection, solutionSubcutaneousNDC, Inc.2015-12-04Not applicableUs
ArticaineArticaine hydrochloride (40 mg/mL) + Epinephrine bitartrate (.005 mg/mL)Injection, solutionSubcutaneousPatterson Dental2014-12-22Not applicableUs
Categories
UNII
D3SQ406G9X
CAS number
23964-58-1
Weight
Average: 284.374
Monoisotopic: 284.119463206
Chemical Formula
C13H20N2O3S
InChI Key
QTGIAADRBBLJGA-UHFFFAOYSA-N
InChI
InChI=1S/C13H20N2O3S/c1-5-6-14-9(3)12(16)15-10-8(2)7-19-11(10)13(17)18-4/h7,9,14H,5-6H2,1-4H3,(H,15,16)
IUPAC Name
N-[2-(methoxycarbonyl)-4-methylthiophen-3-yl]-2-(propylamino)propanimidic acid
SMILES
CCCNC(C)C(O)=NC1=C(SC=C1C)C(=O)OC

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Articaine.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Articaine.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Articaine.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Articaine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Articaine.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Articaine.Investigational, Withdrawn
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Articaine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Articaine.Approved, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Articaine.Experimental, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Articaine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Articaine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Articaine.Approved, Illicit
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Articaine.Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Articaine is combined with Allopregnanolone.Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Articaine.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Articaine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Articaine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Articaine.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Articaine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Articaine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Articaine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Articaine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Articaine.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Articaine.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Articaine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Articaine is combined with Azaperone.Investigational, Vet Approved
AzelastineArticaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Articaine is combined with Baclofen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Articaine.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Articaine.Illicit
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Articaine.Investigational
BenperidolThe risk or severity of adverse effects can be increased when Articaine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Articaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Articaine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Articaine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Articaine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Articaine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Articaine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Articaine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Articaine is combined with Brotizolam.Approved, Investigational, Withdrawn
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Articaine.Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Articaine.Approved, Investigational
BuprenorphineArticaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Articaine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Articaine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Articaine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Articaine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Articaine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Articaine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Articaine.Approved, Illicit, Vet Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Articaine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Articaine.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Articaine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Articaine is combined with Carbinoxamine.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Articaine.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Articaine.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Articaine is combined with Carisoprodol.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Articaine.Experimental
CetirizineThe risk or severity of adverse effects can be increased when Articaine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Articaine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Articaine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Articaine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Articaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Articaine is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Articaine.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Articaine.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Articaine.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Articaine is combined with Chlorzoxazone.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Articaine.Experimental
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Articaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Articaine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Articaine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Articaine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Articaine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Articaine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Articaine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Articaine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Articaine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Articaine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Articaine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Articaine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Articaine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Articaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Articaine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Articaine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Articaine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Articaine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Articaine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Articaine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Articaine is combined with Dapoxetine.Investigational
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Articaine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Articaine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Articaine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Articaine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Articaine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Articaine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Articaine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Articaine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Articaine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Articaine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Articaine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Articaine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Articaine.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Articaine is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Articaine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Articaine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Articaine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Articaine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Articaine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Articaine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Articaine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Articaine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Articaine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Articaine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Articaine.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Articaine.Experimental, Illicit
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Articaine.Approved
DuloxetineThe risk or severity of adverse effects can be increased when Articaine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Articaine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Articaine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Articaine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Articaine is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Articaine is combined with Eltanolone.Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Articaine.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Articaine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Articaine is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Articaine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Articaine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Articaine.Approved
EthanolArticaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Articaine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Articaine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Articaine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Articaine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Articaine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Articaine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Articaine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Articaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Articaine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Articaine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Articaine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Articaine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Articaine.Illicit, Vet Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Articaine.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Articaine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Articaine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Articaine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Articaine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Articaine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Articaine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Articaine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Articaine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Articaine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Articaine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Articaine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Articaine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Articaine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Articaine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Articaine.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Articaine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Articaine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Articaine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Articaine.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Articaine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Articaine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Articaine.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Articaine is combined with Gepirone.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Articaine.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Articaine.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Articaine.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Articaine.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Articaine.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Articaine.Approved, Illicit
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Articaine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Articaine is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Articaine.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Articaine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Articaine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Articaine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Articaine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Articaine.Approved
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Articaine.Approved, Investigational
HydrocodoneArticaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Articaine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Articaine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Articaine is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Articaine is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Articaine is combined with Indiplon.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Articaine.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Articaine.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Articaine.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Articaine.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Articaine.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Articaine.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Articaine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Articaine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Articaine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Articaine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Articaine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Articaine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Articaine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Articaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Articaine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Articaine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Articaine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Articaine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Articaine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Articaine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Articaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Articaine.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Articaine.Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Articaine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Articaine is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Articaine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Articaine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Articaine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Articaine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Articaine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Articaine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Articaine is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Articaine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Articaine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Articaine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Articaine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Articaine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Articaine is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Articaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Articaine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Articaine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Articaine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Articaine is combined with Metaxalone.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Articaine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Articaine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Articaine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Articaine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Articaine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Articaine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Articaine.Approved
MethotrimeprazineArticaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Articaine.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Articaine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Articaine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Articaine.Approved
MetyrosineArticaine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Articaine.Approved, Illicit
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Articaine.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Articaine.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Articaine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved, Investigational
MirtazapineArticaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Articaine.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Articaine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Articaine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Articaine.Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Articaine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Articaine is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Articaine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Articaine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Articaine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Articaine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Articaine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Articaine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Articaine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Articaine.Approved
OpiumThe risk or severity of adverse effects can be increased when Articaine is combined with Opium.Approved, Illicit
OrphenadrineArticaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Articaine.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Articaine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Articaine is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Articaine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Articaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Articaine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Articaine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Articaine.Approved
ParaldehydeArticaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Articaine is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Articaine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Articaine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Articaine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved
PerazineThe risk or severity of adverse effects can be increased when Articaine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Articaine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Articaine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Articaine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Articaine is combined with Phenazocine.Experimental
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Articaine.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Articaine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Articaine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Articaine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Articaine is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Articaine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Articaine.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Articaine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Articaine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Articaine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Articaine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Articaine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Articaine is combined with Pomalidomide.Approved
PramipexoleArticaine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Articaine.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Articaine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Articaine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Articaine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Articaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Articaine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Articaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Articaine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Articaine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Articaine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Articaine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Articaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Articaine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Articaine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Articaine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Articaine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Articaine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Articaine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Articaine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Articaine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Articaine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Articaine is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Articaine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Articaine.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Articaine.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Articaine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Articaine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Articaine is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Articaine is combined with Romifidine.Vet Approved
RopiniroleArticaine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Articaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Articaine.Approved, Investigational
RotigotineArticaine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Articaine.Approved
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Articaine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Articaine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Articaine.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Articaine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Articaine.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Articaine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Articaine.Approved, Vet Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Articaine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Articaine.Investigational
StiripentolThe risk or severity of adverse effects can be increased when Articaine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Articaine.Approved, Investigational
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Articaine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Articaine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Articaine is combined with Sultopride.Experimental
SuvorexantArticaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Articaine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Articaine is combined with Tasimelteon.Approved
Technetium Tc-99m tilmanoceptArticaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Articaine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Articaine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Articaine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Articaine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Articaine.Investigational
ThalidomideArticaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Articaine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Articaine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Articaine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Articaine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Articaine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Articaine is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Articaine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Articaine is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Articaine is combined with Tizanidine.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Articaine.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Articaine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Articaine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Articaine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Articaine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Articaine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Articaine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Articaine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Articaine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Articaine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Articaine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Articaine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Articaine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Articaine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Articaine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Articaine is combined with Triprolidine.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Articaine.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Articaine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Articaine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Articaine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Articaine is combined with Vigabatrin.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Articaine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Articaine is combined with Vinyl ether.Experimental
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Articaine.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Articaine is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Articaine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Articaine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Articaine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Articaine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Articaine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Articaine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Articaine is combined with Zolazepam.Vet Approved
ZolpidemArticaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Articaine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Articaine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Articaine is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Articaine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 3,910,924.

General References
Not Available
External Links
KEGG Drug
D07468
PubChem Compound
32170
PubChem Substance
310264968
ChemSpider
29837
ChEBI
91834
ChEMBL
CHEMBL1093
Drugs.com
Drugs.com Drug Page
Wikipedia
Articaine
ATC Codes
N01BB58 — Articaine, combinationsN01BB08 — Articaine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentIrreversible Pulpitis1
3CompletedTreatmentSpinal Anaesthesia1
4CompletedPreventionAnesthesia of Mucous Membrane1
4CompletedTreatmentGastroscopy1
4CompletedTreatmentIrreversible Pulpitis1
4CompletedTreatmentIrreversible Pulpitis / Pain1
4Not Yet RecruitingTreatmentAnesthesia, Dental / Postoperative pain1
4TerminatedTreatmentAortic Valve Disorder / Atrial Septal Defect (ASD) / Diseases of Mitral Valve / Intracardiac Myxoma1
Not AvailableCompletedTreatmentPulpitis dental1
Not AvailableRecruitingPreventionArterial Hypotension1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solutionDental; Infiltration
InjectionSubmucosal
LiquidInfiltration
Injection, solutionSubmucosal
SolutionInfiltration
Injection, solutionSubcutaneous
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)172-173U.S. Patent 3,910,924.
Predicted Properties
PropertyValueSource
Water Solubility0.0366 mg/mLALOGPS
logP1.9ALOGPS
logP0.96ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)4.42ChemAxon
pKa (Strongest Basic)8.91ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area70.92 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity77.53 m3·mol-1ChemAxon
Polarizability30.8 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as thiophene carboxylic acids and derivatives. These are compounds containing a thiophene ring which bears a carboxylic acid group (or a salt/ester thereof).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Thiophenes
Sub Class
Thiophene carboxylic acids and derivatives
Direct Parent
Thiophene carboxylic acids and derivatives
Alternative Parents
Methyl esters / Heteroaromatic compounds / Amino acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Monocarboxylic acids and derivatives / Dialkylamines / Carboximidic acids / Organopnictogen compounds / Organooxygen compounds / Organic oxides
show 1 more
Substituents
Thiophene carboxylic acid or derivatives / Methyl ester / Heteroaromatic compound / Amino acid or derivatives / Carboxylic acid ester / Carboximidic acid / Carboximidic acid derivative / Carboxylic acid derivative / Secondary aliphatic amine / Monocarboxylic acid or derivatives
show 12 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on June 20, 2014 11:45 / Updated on December 01, 2017 17:19